

HEMORRHAGIC DIATHESSES

ASPECTS OF CLINICAL AND LABORATORY DIAGNOSIS . PRINCIPES OF TREATMENT.

Department of pediatrics

The physiologic role of hemostasis

- **Stopping of hemorrhage in the case of sanguine vessels lesion**
- **Recanalization of sanguine vessels in the case of accidental occlusion**
- **Maintaining of blood in liquid state in vascular lumen**

The components of Hemostasis System

- **Vascular wall**
- **Sanguine cells**
(thrombocytes, erythrocytes)
- **Plasmatic factors of coagulation**
- **Activators and inhibitors of**
fibrinolytic system
- **Anticoagulant factors**

Stages of hemostasis

- **Primary hemostasis**
(white thrombocytary clot)
- **Secondary hemostasis**
(red erythrocytary clot)
- **Fibrinolysis**
(clot lysis)

Components of primary hemostasis

- **Vascular wall**
- **Thrombocytes**

Vascular endothelium

(anticoagulant function)

- Releasing of Prostacycline
- Producing of fibrinolysis tissular activator
- Ensuring the impossibility of contact activation
- Forming of anticoagulant potential

Heparine + Antithrombine III

- Maintaining of dzeta-potential

Vascular endothelium

(procoagulant function)

- Tissue thromboplastin
- Stimulators of thrombocytary functions:
adrenaline, noradrenaline, ADP
- Ensuring of activation through contact of thrombocytes and XII factor
- Synthesis of von Willebrand factor and other factors of coagulation
- Synthesis and releasing of A2 -Thromboxan

Thrombocyetary functions

- **Angiotrophic**
- **Adhesivity**
- **Aggregation**
- **Synthesis, accumulation and releasing**
- **Contractibility**

Thrombocyetary granules

- **α -Granules**
- **Dense granule**
- **Lisosomal granules**
- **Peroxisomes**

Components of α -granules

- **Von Willebrand factor**
- **Fibrinogen**
- **Factor V**
- **Factor P4 (antiheparinic)**

- **Protein S**

Components of dense granules

- **ADP**
- **Serotonin**
- **Calcium ions**
- **Adrenalin**
- **Antiplasmin**

- **ATP**


Thrombocytary factors

- **P1 – thrombocytary accelerator,
identical to factor V of coagulation**
- **P2 – thrombin accelerator**
- **P3 – thrombocytary thromboplastin,
partial thromboplastin**
- **P4 – antiheparinic factor**
- **P5 – coagulation factor, identical to
fibrinogen**
- **P6 – thrombastenin**
- **P9 – fibrin stabilizer factor**
- **P10 – serotonin**
- **P11 – ADP**



Thrombocyetary activators

In vivo			In vitro
In normal		In pathology	
In affected vessel zone	In affected vessel	In blood	
ADP	Collagen	Proteolytic enzymes	ADP
Adrenalin	Von Willebrand factor	Antithrombocyetary antibodies	Thrombin
Serotonin		Ag-Ac compexes	Collagen
Vasopressin		Bacteries	Adrenalin
Plasmin		Viruses	Ristomicin
v Willebrand factor		Tumoral cells	
Thrombin			


Thrombocytes activation



Thrombocytes “in exercise of function”



Thrombocytes “in exercise of function”



Secondary hemostasis.

Plasmatic factors of coagulation

- **F I Fibrinogen**
- **F II Prothrombin**
- **F III Tissular thromboplastin**
- **F IV Ca⁺⁺ ions**
- **F V, VI Proaccelerin, labile factor**
- **F VII Proconvertin, stabile factor**
- **F VIII Antihemophilic globulin**
- **F IX Plasmatic thromboplastin (F Cristhmas)**
- **F X Prothrombinase**
- **F XI Plasmatic thromboplastin predecessor**
- **F XII Factor of contact, f. Hagemann**
- **F XIII Fibrinstabilizer factor , fibrinase**

intrinsic pathway of coagulation


- F XII
- F XI
- F IX
- F VIII
- F X a + F V + F IV
(prothrombinasic complex)

Extrinsic pathway of coagulation

- F III
- F VII
- F X a + F V + F IV
(prothrombinasic complex)

commune pathway of coagulation

- **F X a + F V + F IV**
(protrhombinasic complex)
- **F II (prothrombin – thrombin)**
- **F I (fibrinogen – fibrin)**




Fibrinolytic system

- **Plasminogen**
- **F XII (F. Hagemann, of contact)**
(intrinsec pathway of Plasminogen activation)
- **Tissular (endothelial) activator of Plasminogen**
(extrinsec pathway of plasminogen activation)


Physiologic anticoagulants

- Heparin
- Antitrombin III
- Protein C
- Protein S
- Thrombomodulin
- Antithromboplastin
- α_2 -antitripsin

Hemostasis



Erythrocytary red clot



Hemorrhagic diatheses

**Non homogeneous group of pathologies
characterized clinically
by increased tendency to bleeding**

Classification of HD

- **HD as a result of primary vasculo-thrombocytary hemostasis disorder**
- **HD as a result of secondary hemostasis disorder (coagulopathies)**
- **Mixt HD as a result of primary and secondary hemostais disorder**

HD as a result of primary vasculo-thrombocytary hemostasis disorders

- **Thrombocytopenias**
 - Congenital (Sd. Casabach-Merritt)
 - Acquired (hetero/izo/auto-immune)
- **Thrombocytopathies:**
 - Congenital (TAR, Glanzman, Bernard-Soulier)
 - Acquired (cirrhosis, scorbutus, medicamentous)
- **Vasopathies:**
 - Disease Rendu-Osler-Weber
 - Schönlein-Henoch purpura

HD as a result of secondary hemostasis disorder(coagulopathies)

- **Hypo/a-fibrinogenemia**
- **Hypoprothrombinemia**
- **Hypoproaccelerinemia**
- **Hypoproconvertinemia**
- **Hemophilia A**
- **Hemophilia B (Christmas)**
- **Deficit of F X (Stuart-Prower)**
- **Hemophilia C (Rosenthal)**
- **Hagemann disease (F XII)**
- **Deficit of F XIII (fibrin stabilizer)**

Mixt HD

- **Von Willebrand disease**
- **Disseminated intravascular coagulation (DIC) Syndrome**

Diagnosis of HD

- **Clinical data**
- **Laboratory data**

Clinical diagnosis of HD

???

- Is the hemorrhage a disorder of hemostasis or is a manifestation of local tissue modifications ?
- If there is an affection of hemostasis, which is its character: congenital or acquired?
- Appreciation of clinical manifestations with determining of bleeding type

Types of bleeding

- **Petechial-macular**
- **Hematoma**
- **Mixt**
- **Vascular – purpural**
- **Angiomatous**

Petechial-macular

- Hemorrhagic elements by small calibre (petechiae)
- Nonuniform hemorrhages, by different colour (echimoses)
- Indolor, not tensioned and not stratificate the tissues
- Often are associated with epistaxis, gingivorrhagies, metrorragies
- More seldom- with hemorrhages in sclera, meninx and in stomach
- Appear easily after microtraumatism of capillaries
- Disorder of primary hemostasis (vasopathies, thrombocytopathies/-penias)

Petechial-macular



Petechial-macular



Petechial-macular



Petechial-macular




Hematoma

The following hemorrhages prevail:

- **Massive, profound, tensioned and very painful**
 - **In articulations, muscles, under aponeuroses, in adipose subcutaneous tissue**
 - **extraperitoneal, in peritoneum and intestinal submucosa**
 - **hematomas are easily forming in the place of injections**
 - **They appear during a few hours after surgical intervention or after trauma.**
-
- **Isolated hemorrhage by hematoma type are characteristic for hemophilia A and B.**

Hematoma



Hematoma



Hematoma



Mixt type (petechial-macular-hematoma)

It is delimited by hematoma type by:

- Easier and very rare affection of articulations,
- Predominance of hematomas
in subcutaneous tissue,
extraperitoneal and in internal
organs.

Mixt type (petechial-macular-hematoma)

It differs from petechial-macular type by:

- Massivity of cutaneous elements
- Induration of skin in the places of hemorrhage

Mixt type (petechial-macular-hematoma)

- The bleeding begins by
petechiae, echimoses and epistaxis,
which gradually are transforming in hematomas.
- Characteristic for
von Willebrand disease, DIC syndrome,
profound deficit of F VII and XIII

Vascular – purpural

- They are determined by inflammatory modifications in small calibre vessels and perivascular tissues
- They are followed by local exudative-inflammatory modifications
- Eruptions throw into relief over skin level
- They are hard, form infiltrative pigmented border
- Sometimes they submit to necrosis and form crusts
- They regress with long-time keeping of pigmentation
- They are observed in Schönlein-Henoch purpura, hemorrhagic fevers

Vascular – purpural



Vascular – purpural



Vascular – purpural



Vascular – purpural



Vascular – purpural



Angiomatous

- **Repeated hemorrhages from dysplasiated vessels with certain localization**
- **Without hemorrhages in skin, adipose tissue or in other tissues**
- **The most frequent and more severe are:**
- **Nasal hemorrhages (epistaxis)**
- **Rarer-hemorrhages from gastric, intestinal, renal and pulmonary teleangiectasies.**
- **Laboratory tests don't find disorders of humoral hemostasis system.**
- **In diseases Rendu-Osler-Weber, Louis-Barr,**
- **In hepatic cirrhosis (secondary)**

Laboratory diagnosis of Hemorrhagic diatheses

- **Methods of primary hemostasis appreciation**
- **Methods of secondary hemostasis appreciation**
- **Appreciation of fibrinolytic activity**
- **Appreciation of physiologic anticoagulants**

Primary hemostasis appreciation tests:

Vessels:

- Fragility and capillary resistance

Thrombocytes:

- Number of thrombocytes
- Morphology of thrombocytes
- Bleeding time(Duke, Ivy, Shitikov)
- Clot retraction reaction
- Appreciation of adhesion and aggregation

Fragility and capillary resistance

- **Compression test (with tonometer cuff)**
- **Pinch test**

Rumpel-Leede test

Is performing by hand compression with tonometer cuff.

The applied pressure is equal to medium arterial pressure value.

The application duration constitutes 5 minutes.

After that we number the petechiae appeared on the arm in the area of circle with the diameter of 20 mm.

Normal value: under 10 petechiae,

10-20 petechiae—Rumpel-Leede test is slightly positive (+),

20-30 petechiae – positive test (+ +),

More than 30 petechiae –intense positive test(+ + +).

The test is positive in hereditary vascular disorders, in thrombocytopenies, thrombocytopathies, in hemorrhagic vasculitis.

Pinch test

- At the level of medium third of clavicle the pinch of tegument and adipose subcutaneous tissue is applied. The result is reading after 24 hours.
- Normally the eruptions are not present or 3 – 5 eruptive elements are present.
- The test is positive in vasopathies, thrombocytopathies, thrombocytopenies



The number and morphology of thrombocytes

- **The count of thrombocytes**

(Feisely's technique), is more difficult in comparison with another sanguin elements due to less dimensions of thrombocytes and tendency to aggregation in vitro.

Normal values: 150.000-400.000 / mm³.

The count of thrombocytes decreases in thrombocytopenies, DICS, HUS, autoimmune diseases(SLE), aplastic anemias, leucemias, metaplastic anemias.

- **Morphology of thrombocytes**

- Microcytosis in Wiskott-Aldrich syndrome
- Gigantic thrombocytes in Bernard-Soulier syndrome

Duke's bleeding time

- **The ear lobe is pricked** with an vaccinostyle.

The chronometer is starting at the appearance of first blood drop.

At every 30 seconds the blood drops are collected on the filter paper.

The chronometer is stopping when the paper is not more spotting.

- **Normal value: 3 minutes,**

3-5 minutes – slightly prolonged,
more than 5 minutes – pathologic.

- BT is prolonged in vasculopathies, thrombocytopathies, thrombocytopenias, von Willebrand disease, very rare in severe coagulopathies.

Appreciation of clot retraction

- It characterizes the thrombocytary function in the last phase of coagulation and is directly dependent from the number of thrombocytes.
- 5 mL of venous blood is collected in conic graduated test tube (without stabilizer), a glass stick is placed on the tube center and the tube is incubated at 37 C. The tube periodically is inclined in opposite parts until the clot appearance. After one hour the glass stick is extracted and the volume of remained serum is appreciated.
- **Normal value: 48 – 62%**
- Decreased values: thrombocytopenias,
false decreased - in polyglobulia, erythremia
- False increased values - in anemia, hypofibrinogenemia

Aggregation function examination

- **Diagnosis of hereditary and acquired thrombocytopathies:**
- **Diagnosis of hypoaggregant type hereditary thrombocytopathies (Bernard-Soulier, Glanzmann's thrombastenia)**
- **Diagnosis of hypoaggregant type acquired thrombocytopathies (uremia, cirrhosis, medicaments, toxins)**
- **Diagnosis of hyperaggregant type acquired thrombocytopathies (diabetes mellitus, hyperlipoproteinemias, paraproteinemias)**
- **Antiaggregant therapy control**

Inductors of thrombocytary aggregation

- **ADP**
- **Collagen**
- **Ristomycin**
- Adrenalin
- Serotonin
- Thromboxan A₂

Requests for thrombocytes aggregation investigation

- **The rich in thrombocytes plasma (RTP) is used for investigation**
- **Thrombocytes number in RTP
200 – 250 thousands/mL**
- **Using of different inductors**
- **Using of inductors in different concentrations**
- **Immediate procession of collected probe**
- **Excluding of medicaments that can
influence aggregation**

Obtaining of probes

- **Collection of venous blood using the needle without syringe**
- **(The ratio blood:citrate – 9:1)**
- **Using of plastic test tubes at all stages of investigations**
- **Obtaining and separation of rich in thrombocytes plasma (centrifugation 1000 – 1500 tur/min during 5 – 7 min)**
- **Obtaining of poor in thrombocytes plasma (centrifugation of remained blood 3000 tur/min during 15 min)**

Parameters of aggregation

- **Degree of aggregation**–
Maximal level of aggregation
- **Speed of aggregation**–
Increasing of aggregation degree per minute
- **Aggregation time**–
time of maximal aggregation
- **Duration of „lag“-phase** –
at aggregation with collagen

Hypoaggregation

- **Diminishing of aggregation degree**
- **Diminishing of aggregation speed**
- **Presence of desaggregation**
- **Absence of second aggregation phase**
- **Increasing of „lag“-phase**

Hyperaggregation

- **Increasing of aggregation degree**
- **Increasing of aggregation speed**
- **Presence of monophasic aggregation curve
(merging of I and II aggregation phase)**

Factors that can influence the aggregation of thrombocytes

- **Increase:**


- Oral contraceptives;
- Smoking

- **Decrease:**

- Antiaggregants (aspirin, dipiridamol, ticlid)
- Glucocorticosteroids
- Adrenoblockers
- Blockers of Calcium channels
- Heparin, Fraxiparin
- Vitamins C and E
- Antibiotics (penicillin, carbenicillin)
- Diet (fish diet during 2-3 weeks)


Aggregation with ADP

- Characteristic modification of thrombocytes form.
- Irreversible aggregation.
- Aggregation 52%.
- Dimension of aggregates 6,9 UI.
- Norma: 50 – 80%




Aggregation with collagen

- Lag-phase characteristic in the first minute.
- Aggregation 53%.
- Dimension of aggregates 5,7 μ m.
- Norma: 50 – 70%



Aggregation with Ristomycin

- Aggregation 68%.
- Dimension of aggregates 8,9 UI.
- Norma: 50 – 80%



Differential diagnosis of hemorrhagic diatheses

	ADP		Collagen	Ristomycin
	I phase	II phase		
von Willebrand disease	N	N	N	↓↓↓ / ↑
von Willebrand syndrome	N	N	N	↑ 1,5 – 2 times
Bernard-Soulier syndr.	N	N	N	↓↓
Glantzman's thrombastenia	↓	↓	↓	N
Syndrome of grey thrombocytes	↓	↓ / ↓↓	↓	N
Deficit of granules	↓	Absent	↓	N
Defect of collagen recptor	N	N	↓↓↓	N
Aspirin overdosing	↓	↓	↓	N

Tests of secondary hemostasis appreciation:

- **Global methods**
- **Analytic methods**
- **Quantitative methods**

Global methods

- **Coagulation time by Lee-White method**

The vein is punctured and 2 ml of blood are collected. It is distributed in 2 test tubes in equal quantities. They are placed in water bath at 37° C. The chronometer is started when the blood is getting in syringue. At each minute the test glass is readed by inclination of 45°.

CT is determined in the moment when the test tube can be completely overturned. In this moment the reading of test tube begins at each 2 minute. CT is the time passed from the chronometer starting until appearance of coagulation in the 2-nd test tube.

Normal values: 6-12 minutes.

- **Howell time**

It represents the time of oxalate or citrate plasma coagulation after recalcification.

Besides plasmatic factors, HT appreciates also the thrombocytary function(F3P).

Normal values: 1'10" – 2'10".

There is the main test used for heparin therapy monitoring.

Analytic methods

- **Intrinsic pathway**
 - Partial time of thromboplastin
 - Partial time of activated thromboplastin
- **Extrinsic pathway**
 - Quick prothrombin time (PT)
- **Common pathway**
 - Thrombin time

Intrinsic pathway

- **Partial thromboplastin time (cephalin)**

It allows to appreciate the thromboplastin forming on endogenous pathway (intrinsic).

The technique is similar to that of HT but the supplement of cephaline ensures the independence from F3P.

- **Normal values: 70-110 seconds.**

- It is changed in the deficit of factors

XII, XI, X, IX, VIII, I and severe deficit of factors V and II.

- **Partial time of Activated Thromboplastin**

(cephalin-kaolin).

The adding of kaolin in PTT test excludes the influence of factors XII and XI on coagulation, therefore PTAT being a valuable screening test of antihemophilic factors.

- **Normal values: 35-50 seconds.**

- It is changed in the deficit of factors X, IX, VIII, I
and severe deficit of factors V and II.

Extrinsic pathway

- **Quick's prothrombin time (Quick PT)**

It explores the factors of protrombinic complex (VII, X, V, II) and fibrinogen.

In the presence of tissular tromboplastin and calcium chloride, the normal plasma is coagulating in very short time (10 seconds), rounding the first phase of coagulation (intrinsic).

- **Normal values: 13-15 seconds**

- **It is modified in hepatic affections and vitamin K insufficiency.**

Common pathway

- **Thrombin time**

The adding of thrombin in plasma probe allows to appreciate the fibrin forming, without the first two phases of coagulation.

- **Normal values: 20-30 seconds**

- Prolonged time in hypofibrinogenemias ($< 1,5$ g/l)
or in presence of some circulant anticoagulant.

Hyperfibrinogenemia over 4,0 g/L can take moderate prolonging of TT.

- **Fibrinogen quantity determining**

- Normal values: 2-4 g/l.

Quantitative methods

- Fibrinogen
- Prothrombin
- Calcium in blood serum
- **F VIII**
- **F IX**
- **F XIII**

- **von Willebrand:RCoF**

Content / Activity of coagulation factors

Factor	Naming	Content
I	Fibrinogen	2 – 4 g/l
II	Prothrombin	60 – 150 %
III	Tissue thromboplastin	
IV	Calcium ions	1,9 – 2,7 mmol/l
V	Proaccelerin	60 – 150 %
VII	Proconvertin	65 – 135 %
VIII	AHF A	60 – 145 %
IX	AHF B, f. Christmas	60 – 140 %
X	F Stuart-Prawuer	80 – 120 %
XI	AHF C	65 – 135 %
XII	F Hagemann	65 – 150 %
XIII	Fibrinstabilizer factor	100 %

Laboratory differentiation of coagulopathies

Pathology	BT	PTAT	PT	T T
Hemophilia A	N	↑	N	N
Hemophilia B	N	↑	N	N
Hemophilia C	N	↑	N	N
vWillebrand disease	↑	N or ↑	N	N
Owren disease (F V)	N	↑	↑	N
Alexander dis. (F VII)	N	N	↑	N
Stuart-Prauer disease (F X)	N	↑	↑	N
Deficit of F XII	N	↑	N	N

Crossed probes of correction

For this test are used:

- **Usual plasma from healthy person**

**Contains F: I, II, V, VII, VIII, IX, X, XI,
XII, XIII**

- **Barium sulphate adsorbed plasma**

Contains F: I, V, VIII, XI, XII, XIII

- **serum from healthy person**

Contains F: VII, IX, X, XI, XII

Crossed probes of correction

Deficit factor	PTT	PTAT	TT	Normal plasma	Adsorbed plasma	Serum
II	↑	↑	↑	Corrects	Corrects	Doesn't correct
V	↑	↑	N	Corrects	Corrects	Doesn't correct
VII	↑	N	N	Corrects	Doesn't correct	Corrects
VIII	N	↑	N	Corrects	Corrects	Doesn't correct
IX	N	↑	N	Corrects	Doesn't correct	Corrects
X	↑	↑	N	Corrects	Doesn't correct	Corrects
XI	N	↑	N	Corrects	Corrects	Corrects
XII	N	↑	N	Corrects	Corrects	Corrects

Appreciation of fibrinolysis

- **Time of euglobinic clot lysis**

Normal values: males 150 ± 30 seconds,
females 180 ± 30 seconds.

- **Test for evidence of
Fibrin Degradation Products (FDP).**

Normal values: $<4 \mu\text{g/mL}$

- **Test of fibrin monomers evidence(FMT).**

Appreciation of fibrinolysis

- Time of euglobinic clot lysis
- FDP and FMT
increase in:
- DICS
- Thrombembols

Contain / activity of principal
anticoagulant factors

Factor	Contain or activity in plasma
Antithrombin III	Activity 80 – 120 %
Heparin	0,24 – 0,6 UI/ L
Protein C	Contain in plasma 70 – 130 %
Protein S	Contain in plasma 60 – 140 %

Contain / activity of principal anticoagulant factors

- **Antithrombin III**
- **protein C**
- **protein S**

are decreased in :

- **Thrombophilias**
- **DIC syndrome**

Principles of primary hemostasis disorders treatment

- **Corticotherapy**
- **Vasoprotectors**
- **Immunodepressants**
- **Splenectomy**

Principles of secondary hemostasis disorders treatment

- **Substitution therapy with:**

- **Fresh frozen plasma**

- **Cryoprecipitate**

- **Purified coagulation factors precipitates**

**THANK YOU
FOR ATTENTION**

